Literature DB >> 26996902

Expression of C-X-C chemokine receptor type 7 in otorhinolaryngologic neoplasms.

Tian Tang1, Qing Jie Xia2, Xiaoming Qiao3, Mingrong Xi4.   

Abstract

INTRODUCTION: C-X-C chemokine receptor type 7 (CXCR7) has recently been characterised as a novel receptor for the C-X-C motif chemokine 12 (CXCL12)/stromal cell-derived factor 1-alpha. CXCR7 has been thought to play an important role in the pathogenesis of chronic rhinosinusitis, angiogenesis and tumour metastasis. The present study aimed to examine the expression of CXCR7 in tissue samples of laryngeal cancer and maxillary sinus carcinoma to determine its role in the development of otorhinolaryngologic neoplasms.
METHODS: Samples of otorhinolaryngologic neoplasms were obtained from 17 patients with either nasal polyps (n = 7), laryngeal cancer (n = 5) or maxillary sinus carcinoma (n = 5), and who underwent surgical resection at West China Hospital of Sichuan University. Total RNA was isolated and CXCR7 mRNA expression was examined and quantified by relative real-time reverse transcription polymerase chain reaction. A one-way analysis of variance was performed using SPSS Statistics version 11.0 (SPSS Inc, Chicago, IL, USA) to compare the CXCR7 mRNA levels among the three groups of patients.
RESULTS: All samples tested positive for CXCR7 mRNA. The quantitative results showed that the CXCR7 mRNA levels were highest in laryngeal cancer and lowest in maxillary sinus carcinoma neoplasms, although there was no significant difference among the three samples.
CONCLUSION: CXCL12 and its receptor CXCR7 may contribute to eosinophilic inflammation in patients with chronic sinusitis and nasal polyps. Our results also suggest that CXCR7 may play a role in the progression, metastasis and angiogenesis of otorhinolaryngologic tumours. Copyright: © Singapore Medical Association.

Entities:  

Keywords:  CXCR7; laryngeal cancer; maxillary sinus carcinoma; nasal polyposis

Mesh:

Substances:

Year:  2016        PMID: 26996902      PMCID: PMC4800727          DOI: 10.11622/smedj.2016057

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  20 in total

1.  The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes.

Authors:  Karl Balabanian; Bernard Lagane; Simona Infantino; Ken Y C Chow; Julie Harriague; Barbara Moepps; Fernando Arenzana-Seisdedos; Marcus Thelen; Françoise Bachelerie
Journal:  J Biol Chem       Date:  2005-08-17       Impact factor: 5.157

2.  Hypoxic preconditioning advances CXCR4 and CXCR7 expression by activating HIF-1α in MSCs.

Authors:  Hongbao Liu; Wujun Xue; Guanqun Ge; Xiaohui Luo; Yang Li; Heli Xiang; Xiaoming Ding; Puxun Tian; Xiaohui Tian
Journal:  Biochem Biophys Res Commun       Date:  2010-09-24       Impact factor: 3.575

Review 3.  CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression.

Authors:  Xueqing Sun; Guangcun Cheng; Mingang Hao; Jianghua Zheng; Xiaoming Zhou; Jian Zhang; Russell S Taichman; Kenneth J Pienta; Jianhua Wang
Journal:  Cancer Metastasis Rev       Date:  2010-12       Impact factor: 9.264

4.  Intrinsic molecular factors cause aberrant expansion of the splenic marginal zone B cell population in nonobese diabetic mice.

Authors:  Jessica Stolp; Eliana Mariño; Marcel Batten; Frederic Sierro; Selwyn L Cox; Shane T Grey; Pablo A Silveira
Journal:  J Immunol       Date:  2013-06-05       Impact factor: 5.422

5.  Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells.

Authors:  Ke Zheng; Hong-Yuan Li; Xin-Liang Su; Xiao-Yi Wang; Tian Tian; Fan Li; Guo-Sheng Ren
Journal:  J Exp Clin Cancer Res       Date:  2010-04-11

6.  CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature.

Authors:  Zhenhua Miao; Kathryn E Luker; Bretton C Summers; Rob Berahovich; Mahaveer S Bhojani; Alnawaz Rehemtulla; Celina G Kleer; Jeffrey J Essner; Aidas Nasevicius; Gary D Luker; Maureen C Howard; Thomas J Schall
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-26       Impact factor: 11.205

7.  Lung-selective gene responses to alveolar hypoxia: potential role for the bone morphogenetic antagonist gremlin in pulmonary hypertension.

Authors:  Christine M Costello; Katherine Howell; Edwina Cahill; Jean McBryan; Melanie Konigshoff; Oliver Eickelberg; Sean Gaine; Finian Martin; Paul McLoughlin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-05-09       Impact factor: 5.464

8.  Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer.

Authors:  Shotaro Iwakiri; Nobuya Mino; Tsuyoshi Takahashi; Makoto Sonobe; Shinjiro Nagai; Kenichi Okubo; Hiromi Wada; Hiroshi Date; Ryo Miyahara
Journal:  Cancer       Date:  2009-06-01       Impact factor: 6.860

9.  Evaluation of the presence of B-cell attractant chemokines in chronic rhinosinusitis.

Authors:  Monica Patadia; Julian Dixon; David Conley; Rakesh Chandra; Anju Peters; Lydia A Suh; Atsushi Kato; Roderick Carter; Kathleen Harris; Leslie Grammer; Robert Kern; Robert Schleimer
Journal:  Am J Rhinol Allergy       Date:  2010 Jan-Feb       Impact factor: 2.467

10.  The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer.

Authors:  Jianhua Wang; Yusuke Shiozawa; Jincheng Wang; Yu Wang; Younghun Jung; Kenneth J Pienta; Rohit Mehra; Robert Loberg; Russell S Taichman
Journal:  J Biol Chem       Date:  2007-12-05       Impact factor: 5.486

View more
  2 in total

Review 1.  Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.

Authors:  Weiqiang Zhou; Shanchun Guo; Mingli Liu; Matthew E Burow; Guangdi Wang
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

2.  CXCR7, a Prognostic Biomarker in Cervical Squamous Cell Carcinoma, May Be a Screening Index for Treatment Options at Stages IB1 and IIA1.

Authors:  Danyang Zhao; Wenban Qin; Chuanxiang Zhao; Jianxiong Long; Mujun Li
Journal:  Cancer Manag Res       Date:  2019-12-09       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.